<DOC>
	<DOCNO>NCT02893332</DOCNO>
	<brief_summary>To test add consolidative SBRT TKI EGFR mutate patient less equal 5 metastatic site ( primary + 5 ) improve progression free survival ( PFS ) compare TKI alone .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy ( SBRT ) Newly Diagnosed Advanced Staged Lung Adenocarcinoma ( Sindas )</brief_title>
	<detailed_description>This protocol randomize phase III trial TKI versus consolidative Stereotactic Body Radiation Therapy ( SBRT ) plus TKI patient Stage IV non-small cell lung cancer ( NSCLC ) . Prior accrual trial , patient Stage IV NSCLC treat positive EGFR mutation . Patients few equal 5 site oligometastatic disease randomize toTKI consolidative SBRT sit disease ( follow TKI medical oncologist 's discretion ) . Choices TKI determine medical oncologist base clinical appropriateness .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Newly diagnose metastatic lung adenocarcinoma ( recurrent de novo ) harbor sensitize EGFR mutation ( L858R , exon 19 deletion , G719A , L861Q , S768I , exon 19 insertion ) oligometastatic disease ( ≤5 discrete lesion disease irrespective location , inclusive primary lesion ) : site disease must amenable definitive treatment local therapy ( surgical resection , stereotactic radiosurgery , ablation conventional radiation therapy ) determine surgery , interventional radiology radiation oncology intrathoracic lymph node ( include hilar , mediastinal , supraclavicular nodal disease ) consider 1 discrete lesion . Each brain metastasis include distinct lesion . Patients already start erlotinib eligible long sit disease determine eligible definitive local therapy consensus principal investigator within 12 week patient first take erlotinib . Lung adenocarcinoma histology confirm Karnofsky Performance Status ≥ 70 % Adequate bone marrow , liver renal function , specify : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ≥ 8 g/dL Platelets ≥ 100 x 109/L Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ( except patient document Gilbert 's Syndrome ) AST ALT ≤ 2.5 x ULN ≤ 5 x ULN liver metastases present Serum creatinine ≤ 1.5 x upper limit normal creatinine clearance ≥ 60ml/min patient creatinine level institutional normal . For woman childbearing potential , negative pregnancy test within 14 day prior start treatment Men woman childbearing age must willing use effective contraception treatment least 3 month thereafter Treatment TKI prior develop metastatic disease Patients activate sensitize mutation ( exon 20 insertion , EGFR T790M ) Malignant pleural effusion pleural disease Leptomeningeal disease Any site disease amenable definitively local therapy include surgery radiation therapy Women breastfeed pregnant Concurrent malignancy nonmelanoma skin cancer require active ongoing treatment . Any medical comorbidities would preclude surgery radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>